Breakthrough COVID‐19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients

Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series

(2022) Sophie Caillard et al.   ANNALS OF INTERNAL MEDICINE

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

(2022) Lihong Liu et al.   NATURE

Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients

(2022) Xavier Charmetant et al.   Science Translational Medicine

REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme

(2022) Didier Ducloux et al.   KIDNEY INTERNATIONAL

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

(2022) Emi Takashita et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

(2021) Ilies Benotmane et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Performance of the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC 202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and First Steps towards Global Harmonization of COVID-19 Antibody Methods

(2021) Emma English et al.   JOURNAL OF CLINICAL MICROBIOLOGY

COVID-19 vaccination in kidney transplant recipients

(2021) Sophie Caillard et al.   Nature Reviews Nephrology

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults

(2021) Myron J Levin et al.   Open Forum Infectious Diseases

An initial report from the French SOT COVID Registry suggests high mortality due to Covid-19 in recipients of kidney transplants.

(2020) Sophie Caillard et al.   KIDNEY INTERNATIONAL